|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 2007;83:1766-1767
© 2007 The Society of Thoracic Surgeons
Department of Cardiovascular & Thoracic Surgery, University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8879
(Email: michael.jessen@utsouthwestern.edu).
| The first 20% of the full text of this article appears below. |
The development of cardiopulmonary bypass (CPB) more than 50 years ago enabled the correction of previously untreatable cardiac defects. However, extracorporeal circulation came with a cost: it caused adverse effects from the initiation of a systemic inflammatory response from the production of fat and fibrin emboli and from hemodilution. To counteract these problems, CPB circuitry evolved with advances in oxygenator design, centrifugal pumps, biocompatible surface coatings, and recently with reductions in circuit size.
This report by Huybregts and colleagues [1]
Related Article
Ann. Thorac. Surg. 2007 83: 1760-1766.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |